Adjuvant chemotherapy for stage II nonseminomatous germ-cell tumors Journal Article

  


Authors: Kondagunta, G. V.; Motzer, R. J.
Article Title: Adjuvant chemotherapy for stage II nonseminomatous germ-cell tumors
Abstract: Management options for patients with stage II nonseminomatous germ-cell tumors (NSGCT), completely resected at retroperitoneal lymph node dissection (RPLND), include 2 cycles of adjuvant cisplatin-based chemotherapy, or close surveillance, with chemotherapy reserved for patients who relapse. Both options are associated with cure in an equally high percentage of patients. The decision to choose one of these options over the other is influenced by the extent of the tumor resected and patient compliance. Surveillance is a strong consideration for patients with low-volume nodal disease at RPLND (pN1), because the relapse proportion is 30% or less. In contrast, patients with highvolume nodal involvement at RPLND (pN2) have a relapse rate of 50% to 90% with surveillance alone. Adjuvant chemotherapy is the preferable option in the latter group. A prospective trial of 2 cycles of etoposide plus cisplatin adjuvant chemotherapy for patients with pN2 tumors showed that this regimen was highly effective in achieving relapse-free survival. Copyright 2002, Elsevier Science (USA). All rights reserved.
Keywords: cancer survival; clinical trial; review; cancer recurrence; cisplatin; drug efficacy; skin toxicity; antineoplastic agents; adjuvant therapy; cancer adjuvant therapy; chemotherapy, adjuvant; cancer staging; neurotoxicity; antineoplastic agent; lymph node dissection; lymph node excision; treatment indication; lung toxicity; nephrotoxicity; etoposide; stomatitis; antineoplastic combined chemotherapy protocols; antineoplastic agents, phytogenic; cyclophosphamide; vinblastine; cancer size; testicular neoplasms; patient compliance; dactinomycin; bleomycin; non seminomatous germinoma; germinoma; nonseminomatous germ cell tumors; humans; human; male; priority journal; stage ii
Journal Title: Seminars in Urologic Oncology
Volume: 20
Issue: 4
ISSN: 1081-0943
Publisher: W.B. Saunders Co.  
Date Published: 2002-11-01
Start Page: 239
End Page: 243
Language: English
DOI: 10.1053/suro.2002.36975
PUBMED: 12489056
PROVIDER: scopus
DOI/URL:

http://www.scopus.com/inward/record.url?eid=2-s2.0-0036864942&partnerID=40&md5=07e83621bacefd20f2984abe0ebb1d7e
Notes: Export Date: 14 November 2014 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Gnanamba Kondagunta
    46 Kondagunta
  2. Robert Motzer
    1243 Motzer
Related MSK Work